I don't understand the FDA point either. Too bad. The

New Post Public Reply Private Reply Replies (3) Message Board
plutonium zeynoc #2077
695
I don't understand the FDA point either.

Too bad. The concept is very easy to understand.

This is my last post, so when I push the button, this is a good bye. All of the geniuses on this board can then talk all about share price. and bash KB because someone has to be to blame for shareholders' stock buying decisions.

In my humble opinion, when share price is all that is important, the posters become disconnected from the company and business DECN. Some never cared and it was always about share price. Nonetheless zeynoc I will explain the FDA issue for you.

DECN is demanding $400 - $700 million from J&J. Part of that demand results from a well founded belief that DECN's patents are being infringed by J&J's OneTouch Ultra and OneTouch Select diabetic test strips. OneTouch Select only sells in international markets. How stupid is that plan? Why would anyone sell a product internationally without developing a domestic market. Stupid, stupid, stupid. But for all of that stupidity J&J can be dumb all they want and continue to collect $300 million each year from primarily third world buyers for their OneTouch Select products. But I digress.

I have read all of the pleadings in four Federal lawsuits between DECN and J&J. Throughout all of those 6+ years of pleadings, J&J has played their message board theme: DECN sucks. Mr. Berman is a crook. DECN shareholders hate DECN, so any customers DECN has probably hate them too. DECN has no money and what money they do have was extorted from shareholders. Of the almost 700 Federal filings in these four Federal lawsuits, roughly 475 were filed by J&J and within all of those documents, the iHub message board opinions of DECN are manifest.

And now we come to Monday. Dr. Zem posted that there will be a hearing in Nevada Federal court. That much unfortunately is not true. At a hearing the lawyers, principals and attendees can see how the judge reacts to the pleadings and the oral arguments. At a hearing the judge might just dismiss the J&J Motion and force the litigants into Mediation. But alas, that is not the case. J&J will file their pile of steaming poop, and the judge will take until proobably the end of October to rule. So, what is true is that J&J gets one more written shot at convincing the judge that DECN sucks, Mr. Berman is a crook. DECN shareholders hate DECN, so any customers DECN has probably hate them too. DECN has no money and what money they do have was extorted from shareholders. And that is it. One lonely chance to overcome impossible (at this stage) odds.

I know that J&J will fail at this attempt. The lawyers for both sides know. The judge and his clerks (the real review professionals) all know this and have already made up their minds. The case will proceed, and the parties will be ordered to Mediation.

But my share price paramount friend zeynoc. Do you think the outcome of the Motion will be acceptable to J&J? Their goal is to drag the case out, lower their exposure (they believe time and foot dragging lowers liability -- and they may be right). Monday begins the first BIG strategic event. J&J has known since August 28 they were going to lose the Motion, and all that goes with it.

Court rulings are very, very important. J&J is going to lose this one and this one is BIG, but J&J is still J&J. So, if J&J's plan is to paint DECN like message board posters do: DECN sucks, Mr. Berman is a crook. DECN shareholders hate DECN, so any customers DECN has probably hate them too. DECN has no money and what money they do have was extorted from shareholders, etc. etc. then they are not going to just give up. The court case may move to third gear, but J&J's goal of destroying DECN has not changed.

So here comes the BIG point. What can J&J do that would have the same desired effect. that is, what can J&J do to force DECN to spend big money to survive. What can they do? They can go directly to the post-market group at the FDA and twist them against DECN like on steroids. And that would have the biggest desired effect because the J&J complaints (read: lies) are totally confidential. And the FDA would be only too happy to help out J&J, because FDA people in their mid to late-30s always look to move from the colorless government directly to the private sector, and what better place to work than J&J.

Now zeynoc, you have your own views about how the world works. But in these matters I actually have first hand experience -- many times over. Do you understand THAT? This will become all about the DARK SIDE of the industry if J&J loses in court. Take it to the bank, count on it.

So, let's do whatever we can to force out the only guy who beat J&J and the J&J influenced FDA. and that, in the share price paramount world would be justice. Let's force out the CEO and focus on the share price for the 90 days the company would have to live. I truly hope one or more shareholders come in and take over the company. I am a retired guy and I can afford my loss on DECN stock, so I would love to be a voyeur if shareholders move to force KB out and focus the company on share price.

And with that. Good bye.



1

Decision Diagnostics Corp (DECN) Stock Research Links

DECN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rain Agent Vaults: Revolutionizing Payments with AI

Updated Category News Views 123

Innovative Payments with AI Power Alright, folks, Rain's gone and done something that's probably going to shake things up in the payments world—'cause they've given AI agents the ability to handle money like never before. We're not just talking about some run-of-the-mill integration here. This is a genuine game changer, promising to make agents as financially savvy as...

Continue Reading
ProBio, AbTis Forge Bond for Next-Gen Oncology ADCs

Updated Category News Views 99

Deal or No Deal: ProBio's New Licensing Agreement In the ever-evolving realm of biopharmaceuticals, ProBio's recent handshake with South Korea's AbTis is stirring the pot. The shot-callers at ProBio are passing the baton to AbTis, giving them a crack at developing a thumping new therapeutic antibody asset aimed squarely at oncology targets. Pretty slick move if you ask...

Continue Reading
Alogent's Unify Snags Award for Innovation and Impact

Updated Category News Views 104

Innovation That Captures Attention Alogent sure did grab the spotlight with their Unify platform walking away with a Credit Union Times Luminaries Award. The name of the game here is deposit processing innovation—the kind of buzz that turns heads in the banking world. This recognition isn't just another plaque for the lobby; it's a testament to a significant stamp on...

Continue Reading
Sokolove Law Wins $28.8M Verdict for Misdiagnosis Case

Updated Category News Views 122

Jury Awards $28.8 Million in Misdiagnosis Case Well, here's a tale that's bound to ruffle some feathers in the medical community—$28.8 million tossed on the table because an emergency room missed a life-threatening aortic aneurysm. For the uninitiated, this isn't just chump change; it's the cost of dropping the ball when the stakes are as high as a human life. A jury in...

Continue Reading
FirstDigital Expands Fiber Network in Utah and Arizona

Updated Category News Views 86

Weaving a Web of Connectivity Let's talk about FirstDigital putting its shoulder to the wheel in Utah and Arizona. They're expanding their redundant fiber network to rope in more businesses under their umbrella of connectivity. This ain't just another dry IT endeavor—it's about building a safety net for our ever-connected world. The Stakes of Network Disruption You know...

Continue Reading
Jubilant Eyes MPN Breakthrough with JBI-802 Data at ASH

Updated Category News Views 73

Presenting the Case for JBI-802 From the bustling circus of drug development, here comes Jubilant Therapeutics, strutting their stuff with JBI-802, a dual inhibitor designed to tackle myeloproliferative neoplasms (MPNs) with a one-two punch. Now, they're set to drop some spicy deets at the 68th ASH Annual Meeting in New Orleans this December. So what's the fuss about?...

Continue Reading
Alyssa Bunch: Big Moves in Tennessee Real Estate

Updated Category News Views 104

Navigating the Tennessee Real Estate Maze If you're talking about where the real estate action happens in Tennessee, you'd better mention Alyssa Bunch, the Vanderbilt-educated dynamo who turns the unforsale into the must-buy. Most of the deals she orchestrates are invisible to the public eye until they're all but written in ink and ready to reshape landscapes—or, more...

Continue Reading
Bakersfield Sees Spike in Crashes Post Time Change

Updated Category News Views 83

Evening Darkness and Safety Concerns Folks, it seems Bakersfield streets transform into a battlefield once the clock falls back. With darkness creeping in earlier, those evening hours right after the time change see a sobering uptick in accidents. According to an analysis by Chain | Cohn | Clark, pedestrian and bicyclist crashes from 5 to 7 p.m. double. It's not just...

Continue Reading
IASO Bio's In Vivo CAR-T: A Game Changer for Oncology?

Updated Category News Views 5

You ever feel like you're watching history happen right in front of you? That's the vibe with IASO Bio's latest move in the realm of oncology. This outfit just scored a major victory, getting China's NMPA and the U.S. FDA to greenlight their IASO208, a CD20-targeting in vivo CAR-T therapy. It's not every day you see a company land dual regulatory nods like...

Continue Reading
Zephyr's Alto Hood: Redefining Kitchen Versatility

Updated Category News Views 75

An Artist in the Kitchen Who knew a kitchen hood could be a canvas, right? Zephyr, always a punch above the ordinary in kitchen design, has pulled another rabbit out of their hat with the Alto Wall Custom Hood. Forget blending in; this piece is about standing out and shouting style—all while keeping your cooking area fresh. Options Galore The Alto Hood isn't about...

Continue Reading

Top 5 Most Recently Viewed Articles

Constellation Brands Schedules Earnings Call for Q2 2026

Updated Category News Views 395

Constellation Brands Sets New Reporting Date Constellation Brands, Inc. (NYSE: STZ), a prominent player in the beverage alcohol sector, has recently revised its reporting schedule for the financial results of its second quarter, which ended on August 31, 2025. The new reporting date is set for October 6, 2025, after the markets close. Investors and analysts will be able...

Continue Reading
Bullish Trends Continue for Charter Communications in Options Market

Updated Category News Views 212

Analyzing the Recent Options Trends of Charter Communications The options market is bustling with activity around Charter Communications, indicating a strong bullish sentiment. Investors with significant capital are positioning themselves favorably, potentially anticipating upward price movements for the stock, CHTR. Summary of Options Trading Activity Examining the...

Continue Reading
California Water Service Group's Insights on Sustainability Efforts

Updated Category News Views 386

California Water Service Group Advances Sustainability Initiatives In its latest report, California Water Service Group (NYSE: CWT) has unveiled significant progress on various sustainability efforts aimed at minimizing its environmental footprint and enhancing corporate responsibility. This comprehensive overview showcases the Group's dedication to maintaining high...

Continue Reading
Deadline Approaches for Outset Medical Class Action Investors

Updated Category News Views 50

Important Deadline for Outset Medical Investors Investors, it’s time to stay alert! There’s an upcoming deadline that you need to be aware of regarding the class action lawsuit against Outset Medical, Inc. This lawsuit concerns investors who purchased or acquired securities of Outset Medical during a specific period. With the deadline looming, many individuals may be...

Continue Reading
Investors Losing from ASML Holding N.V. Should Seek Justice

Updated Category News Views 145

Investors' Alert: Class Action Against ASML Holding N.V. ASML Holding N.V. (NASDAQ: ASML) is currently facing a class action securities lawsuit that aims to defend the interests of its investors who may have suffered financial losses. This legal move is significant, especially for those who have been adversely affected by certain events within the semiconductor industry....

Continue Reading